Drug granted orphan designation for chemo-induced ototoxicity

Print Friendly, PDF & Email


Child with cancer
Photo by Bill Branson
The US Food and Drug Administration (FDA) has granted orphan drug designation to SENS-401 to be used for the prevention of platinum-induced ototoxicity in pediatric patients. Platinum-based chemotherapies, particularly cisplatin, can induce severe hearing loss in cancer patients, but there is no pharmaceutical agent approved to treat... [Read Article]
Print Friendly, PDF & Email

Team characterizes RIMs in childhood cancer survivors

Print Friendly, PDF & Email


Child with cancer
Photo by Bill Branson
Neuroscientists say they have uncovered genetic differences between radiation-induced meningiomas (RIMs) and sporadic meningiomas (SMs). Their work suggests RIMs have a different “mutational landscape” from SMs, a finding that may have “significant therapeutic implications” for childhood cancer survivors who undergo cranial radiation. Gelareh Zadeh, MD, PhD,... [Read Article]
Print Friendly, PDF & Email

ATO enables anthracycline reduction in pediatric APL

Print Friendly, PDF & Email


Child with leukemia
Photo by Bill Branson
Consolidation therapy that includes arsenic trioxide (ATO) can decrease anthracycline dosing by about 40% in children and young adults with acute promyelocytic leukemia (APL), according to new research. And it can accomplish this without compromising survival in standard-risk patients. Outcomes for high-risk patients compared favorably to other pediatric... [Read Article]
Print Friendly, PDF & Email